54

6

Logo

SeaBeLife Biotech

Company | France
1

followers

Primary tabs

About your organization

SeaBeLife is a French preclinical stage biotech company set up in 2019 by Morgane Rousselot, PhD., CEO and 3 scientits inventors of the technology. We develop a new disruptive therapeutic approach expected to halve the medical burden including the death rate of severe pathologies without effective treatment. For that, we develope First-In-Class Drugs based on a plateform technology: small molecules which stop the death of the cells and can prevent full organ failure. We have a pipeline of 100 active molecules protected by patents exclusively licensed to SeaBeLife. Two assets are under preclinical development:

- SBL01 to treat the rare but severe life-threatening Acute Liver Injuries (ALI) diseases that represent a social and economic burden due to prolonged hospitalization, mostly in intensive care units, accompanied by multiple complications that often lead to critical organ failure. ALIs are fatal in 30% of cases, despite the progress in intensive care and liver transplantation.

-SBL02 to prevent the loss of vision of patients with Dry-AMD, the first cause of blindness in the over 50 years old affecting more than 5 million patient worldwide each year. Patient mobility is severely impacted, resulting in a loss of independence and Vision loss can lead to reduced quality of life in patients.

SeaBeLife is looking for 2M€ investment to bring its 2 lead compounds to the clinic and sign off its first deal with pharmaceutical company.

Network (0)

There are no organizations in the network.

Dataroom

You are not connected

A certain number of contents are currently hidden from you, and you do not have access to the linking functionalities.

Log in or register To access the complete range of contents and functionalities, simply subscribe. The subscription process is quick and free of charge.

Recent activity

You are not connected

A certain number of contents are currently hidden from you, and you do not have access to the linking functionalities.

Log in or register To access the complete range of contents and functionalities, simply subscribe. The subscription process is quick and free of charge.